View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 30, 2021

Coronavirus company news summary: LUCIRA™ CHECK IT Covid-19 home test receives FDA authorisation for over-the-counter sale – Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 test to be used in DIRECT study

By Chloe Kent

Converge Technology Solutions and Lucira Health have received US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the over-the-counter sale of the LUCIRA™ CHECK IT test kit for Covid-19. The test can be self-administered by an individual at home and get results in 30 minutes. The developers claim the test has PCR-level molecular accuracy.

The University of Utah, ARUP Laboratories and Techcyte have partnered to develop NanoSpot.AI, a rapid Covid-19 antibody test. The test is performed on a blood sample obtained through a finger prick and can provide results in less than five minutes. Currently under clinical studies for validation, the test could be utilised to determine the priority for vaccination or quick testing for travel and immigration purposes.

Oxford Immunotec will utilise its T-SPOT® Discovery SARS-CoV-2 kit for T-cell testing in the DIRECT clinical study, which is being conducted to determine the immune response of ethnic minority healthcare workers to Covid-19 infection or vaccination. The company is conducting the study in collaboration with researchers at the University of Leicester and is funded through the National Core Studies group.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU